This post discusses Bershad et al. (2015), “Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans,” published in Psychoneuroendocrinology.

In 2015, researchers at the University of Chicago gave 48 healthy adults either placebo, 0.2 mg, or 0.4 mg of sublingual buprenorphine and then put them through the Trier Social Stress Test — a standardized lab procedure designed to reliably induce psychosocial stress. Participants had to give a speech in front of interviewers and a video camera, then do mental arithmetic under pressure.

What they found was striking. Both doses of buprenorphine completely blocked the cortisol spike that normally follows social stress. The placebo group showed the expected sharp rise in salivary cortisol during and after the stress task. The buprenorphine groups did not.

Both doses also reduced how threatening participants rated the task before it began and increased their satisfaction with their own performance afterward. This wasn’t sedation or impairment — actual task performance was unaffected. Neither dose changed heart rate or blood pressure responses to the stress. The drug specifically dampened the hormonal and subjective experience of social threat, without blunting the ability to function under it.

An important detail: participants on 0.2 mg did not report feeling “high.” Only the 0.4 mg group showed increased ratings of feeling high, along with nausea. The stress-dampening effect was present at both doses, but the lower dose achieved it without any subjective drug effect.

What the authors concluded — and what they missed

The paper ends with a suggestion that buprenorphine’s stress-dampening properties may contribute to the “non-medical use of opioid drugs.”

I think this framing misses something important.

If buprenorphine reduces the cortisol response to social stress, and if people with BPD have a dysregulated endogenous opioid system that amplifies interpersonal threat and distress, then using buprenorphine to reduce that stress response isn’t non-medical use. It is treating the condition.

The study was conducted in healthy adults. But the effect it demonstrated — blunting the body’s alarm response to social evaluation — maps directly onto one of the most disabling features of BPD: interpersonal hypersensitivity. When every interaction carries the weight of potential rejection, judgment, or abandonment, the stress response isn’t just uncomfortable. It’s paralyzing.

Reducing that response isn’t recreational. It’s therapeutic. And calling it anything else obscures a mechanism that could help explain why low-dose buprenorphine works for some people with BPD in ways that other medications have not.

What this looks like in practice

I take 0.2 mg of sublingual buprenorphine in the morning and 0.1 mg at night. This is my second time on the medication — I restarted in November 2025 after pausing treatment for over a year to see whether I could manage symptoms through diet and inflammation control alone.

At my current dose, I do not feel high. I don’t feel sedated. I don’t feel altered. What I feel is a noticeable reduction in how stressful social interaction is.

Before medication, I had to hype myself up for a lot of ordinary interactions. Sending an email could paralyze me. Not because the email was complicated or high-stakes, but because any interaction with another person carried the implicit risk of rejection, judgment, or misunderstanding — and my nervous system treated that risk as a threat.

Now I’m cold-emailing researchers. I’m reconnecting with friends I haven’t spoken to in years. I can tolerate rejection. I no longer have to avoid interactions for fear of them dysregulating me.

The Bershad study helps explain why.

If buprenorphine suppresses the cortisol response to social stress at 0.2 mg — the same dose I take each morning — then what I’m experiencing isn’t just subjective. There’s a measurable physiological mechanism: my body is no longer mounting a full stress response to routine social situations. The threat signal is quieter, and I can act instead of bracing.

What 0.4 mg felt like

In the study, participants on 0.4 mg reported feeling high and experienced nausea. When I first started buprenorphine in 2022, my doctor started me at 0.5 mg. I had nausea, vomiting, and confusion. I felt altered in a way that was distinctly unpleasant, not therapeutic. Lowering the dose resolved the side effects completely.

This aligns with the study’s dose-response pattern. The stress-dampening effect was fully present at 0.2 mg — without the subjective drug effects that appeared at 0.4 mg. More is not better. In my experience, the therapeutic window for BPD-related symptoms is often below the threshold where you’d feel “high,” though this can vary with severity. Some opioid-naive patients may ultimately require higher doses. That said, starting low is important to minimize side effects, especially since meaningful benefits can occur at these lower doses.

Dose timing and duration

The study administered buprenorphine 90 minutes before the stress task, and peak plasma concentrations occur 90–360 minutes after sublingual ingestion. The cortisol-blocking effect was clearly present during this window.

This has practical implications for split dosing. If I take my morning dose and it reaches effective levels within about 90 minutes, that covers most of the day when I’m likely to encounter social stressors. For my evening dose, timing it roughly 90 minutes before the window I need coverage — rather than right before bed — may provide more meaningful stress-dampening during evening interactions while still supporting overnight regulation.

I’m still optimizing this, and individual pharmacokinetics vary. But the study gives a concrete frame for thinking about when the drug is active, not just whether it’s present.

This is a medical use

BPD involves dysregulation of systems that govern how we experience social threat, attachment, rejection, and emotional pain. If buprenorphine dampens the stress response to social evaluation — as this study clearly shows — then prescribing it for people whose lives are organized around avoiding that very stress is not off-label curiosity. It is targeting a core mechanism of the disorder.

The endogenous opioid system is involved in social bonding, separation distress, and the regulation of the HPA axis. Buprenorphine acts on that system. BPD appears to involve dysregulation of that system. The connection is not speculative — it’s the most straightforward explanation for why this drug helps.

We don’t frame SSRIs for depression as “non-medical use of serotonergic drugs.” We don’t frame stimulants for ADHD as “non-medical use of amphetamines.” When a medication targets the system that’s dysregulated, using it to treat that dysregulation is medicine.

People with BPD who find relief from buprenorphine are not chasing a high. They are regulating a system that was never adequately treated by other means.

Bershad AK, Jaffe JH, Childs E, de Wit H. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology. 2015;52:281-288. doi:10.1016/j.psyneuen.2014.12.004